Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1965 1
1966 1
1967 1
1973 1
1988 1
1989 2
1991 1
1992 2
1993 3
1994 1
1995 1
1997 2
2003 3
2004 3
2005 2
2006 3
2007 6
2008 1
2009 5
2010 5
2011 6
2012 7
2013 4
2014 3
2015 4
2016 4
2017 10
2018 8
2019 4
2020 3
2021 2
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. Among authors: bellei m. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Gini G, Tani M, Tucci A, Marcheselli L, Cesaretti M, Bellei M, Pascarella A, Ballerini F, Petrini M, Merli F, Olivieri A, Lanza F, Annibali O, Zilioli VR, Liberati AM, Tisi MC, Arcari A, Marino D, Musuraca G, Pavone V, Fabbri A, Pozzi S, Mannina D, Plenteda C, Celli M, Luminari S. Gini G, et al. Among authors: bellei m. Blood. 2023 Oct 26;142(17):1438-1447. doi: 10.1182/blood.2022019173. Blood. 2023. PMID: 37418685 Clinical Trial.
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Zucca E, et al. Among authors: bellei m. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. J Clin Oncol. 2017. PMID: 28355112 Free article. Clinical Trial.
Prognostic factors in low-grade non-Hodgkin lymphomas.
Federico M, Molica S, Bellei M, Luminari S. Federico M, et al. Among authors: bellei m. Curr Hematol Malig Rep. 2009 Oct;4(4):202-10. doi: 10.1007/s11899-009-0027-0. Curr Hematol Malig Rep. 2009. PMID: 20425409 Review.
Redox properties of heme peroxidases.
Battistuzzi G, Bellei M, Bortolotti CA, Sola M. Battistuzzi G, et al. Among authors: bellei m. Arch Biochem Biophys. 2010 Aug 1;500(1):21-36. doi: 10.1016/j.abb.2010.03.002. Epub 2010 Mar 6. Arch Biochem Biophys. 2010. PMID: 20211593 Review.
Redox thermodynamics of B-class dye-decolorizing peroxidases.
Pfanzagl V, Bellei M, Hofbauer S, Laurent CVFP, Furtmüller PG, Oostenbrink C, Battistuzzi G, Obinger C. Pfanzagl V, et al. Among authors: bellei m. J Inorg Biochem. 2019 Oct;199:110761. doi: 10.1016/j.jinorgbio.2019.110761. Epub 2019 Jul 11. J Inorg Biochem. 2019. PMID: 31325671 Free article.
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
André MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Brière J, Clément-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N. André MPE, et al. Among authors: bellei m. Cancer Med. 2020 Sep;9(18):6565-6575. doi: 10.1002/cam4.3298. Epub 2020 Jul 25. Cancer Med. 2020. PMID: 32710498 Free PMC article. Review.
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.
Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J. Eichenauer DA, et al. Among authors: bellei m. Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14. Haematologica. 2017. PMID: 28912173 Free PMC article. Review.
BEACOPP or no BEACOPP?
Federico M, Bellei M, Cheson BD. Federico M, et al. Among authors: bellei m. Lancet Oncol. 2013 Nov;14(12):e487-8. doi: 10.1016/S1470-2045(13)70483-2. Lancet Oncol. 2013. PMID: 24176562 No abstract available.
96 results